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Abstract 
Background: Air travel may imply a health hazard for patients with cystic fibrosis (CF) due to hypobaric environment 
in the aircraft cabin. The objective was to identify pre-flight variables, which might predict severe hypoxaemia in adult 
CF patients during air travel.
Methods: Thirty adult CF-patients underwent pre-flight evaluation with spirometry, arterial oxygen tension (PaO2), 
pulse oximetry (SpO2) and cardiopulmonary exercise testing (CPET) at sea level (SL). The results were related to the 
PaO2 obtained during a hypoxia-altitude simulation test (HAST) in which a cabin altitude of 2438 m (8000 ft) was 
simulated by breathing 15.1% oxygen.
Results: Four patients fulfilled the criteria for supplemental oxygen during air travel (PaO2 HAST < 6.6 kPa). While walk-
ing slowly during HAST, another eleven patients dropped below PaO2 HAST 6.6 kPa. Variables obtained during CPET 
(PaO2 CPET, SpO2 CPET, minute ventilation/carbon dioxide output, maximal oxygen uptake) showed the strongest cor-
relation to PaO2 HAST.
Conclusions: Exercise testing might be of value for predicting in-flight hypoxaemia and thus the need for supple-
mental oxygen during air travel in CF patients.
Trial registration The study is retrospectively listed in the ClinicalTrials.gov Protocol Registration System: NCT01569880 
(date; 30/3/2012)
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Background
Due to medical improvement and preventive initiatives, 
both quality of life and the longevity of patients with 
cystic fibrosis (CF) have increased substantially during 
the past 10–20 years. Today, CF-patients participate in all 
aspects of modern life, including air travelling. However, 
due to the hypobaric environment in the aircraft cabin, 
air travel may imply a health hazard for CF-patients, 
most of them suffering from chronic pulmonary disease. 
The ambient oxygen partial pressure inside the aircraft 
cabin during commercial air travel is reduced, corre-
sponding to an altitude of 2438  m (8000  ft) at maximal 
cruising altitude [1]. CF-patients are therefore prone to a 
substantial reduction in the partial arterial oxygen pres-
sure (PaO2) during the flight.
Guidelines concerning pre-flight evaluation of patients 
with pulmonary disease have suggested various screen-
ing variables as normative, such as oxygen saturation at 
sea level and spirometric values [2–4]. In case of doubt, 
a hypoxia-altitude simulation test (HAST) has been rec-
ommended as decisive. HAST is performed by breathing 
a gas mixture containing 15.1% oxygen corresponding 
to an altitude of 2438 metres [5]. Administration of sup-
plemental oxygen during flight is advised if PaO2 drops 
below 6.6 kPa during the test [3, 4].
Several studies addressing pre-flight evaluation of 
lung patients have been published, mainly on patients 
with chronic obstructive pulmonary disease (COPD) 
[6–11]. However, these results may not be applicable to 
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the CF-population. CF-patients are generally younger, 
have fewer additional (cardiovascular) risk factors, and 
the pathophysiology causing hypoxaemia may differ 
from that of COPD [12]. The literature regarding in-flight 
hypoxaemia in patients with CF is limited [13–18], and 
reliable screening methods for predicting development of 
severe in-flight hypoxaemia in CF patients have not been 
identified [3]. In COPD patients, it has been claimed that 
pre-flight measurement of arterial blood gases (PaO2) is 
the single most helpful test for predicting in-flight PaO2 
in lung patients [19]. In previous reports on CF patients, 
however, arterial blood gas measurements have, to our 
knowledge, not been performed. In addition, recent stud-
ies have advocated that exercise testing is of value for 
predicting which patients will develop in-flight hypoxae-
mia [20, 21], but this aspect is also lacking in studies on 
CF-patients.
Given the widespread use of air travelling in adult 
patients with CF [16], further knowledge is needed to 
identify pre-flight variables which might predict in-flight 
hypoxaemia. The aims of the present study were to inves-
tigate the relationship between hypoxaemia achieved 
during HAST (PaO2 HAST) and sea level values of pulmo-
nary function, arterial blood gases, pulse oximetry and 
cardiopulmonary exercise test (CPET) variables. In addi-
tion, the effect of slow walking during hypoxic exposure, 
simulating slow walking along the aircraft’s aisle, was 
studied.
Methods
From January 2006 to December 2008, all adult CF 
patients referred to the National Center for Cystic Fibro-
sis at Oslo University Hospital, Norway for comprehen-
sive assessment, and who were in a stable phase of their 
disease, were invited to participate in this cross-sectional 
HAST study. Criteria for eligibility were >16 years of age 
and sputum test negative for Burkholderia cepacia and/
or methicillin resistant Staphylococcus aureus.
The CF diagnosis was confirmed both genetically and 
clinically. The Regional Committee for Medical Ethics 
(Oslo, Norway) approved the study, and written informed 
consents were obtained by all participants. The study is 
retrospectively listed in the ClinicalTrials.gov Protocol 
Registration System (NCT01569880).
Pre‑flight tests
Pre-flight tests were obtained at sea level (30 m above sea 
level, hereafter referred to as sea level) while breathing 
ambient air. Lung function tests were performed using 
Vmax Series, (VIASYS, Yorba Linda, USA) [22]. After 
5  min at rest in the sitting position, the percutaneous 
oxygen saturation (SpO2 SL) was measured with a finger 
probe using a stationary pulse oximeter (NONIN 8600, 
Medical, Inc., Minneapolis, USA), and arterial blood gas 
samples were drawn from a radial artery cannula. The 
samples were immediately analysed (ABL 700 series, 
Radiometer, Copenhagen, Denmark).
CPET was performed by walking and running on a 
treadmill (Jaeger LE 100, Würzburg, Germany) until 
exhaustion, using a progressive 1 min step protocol. Gas 
exchanges and ventilatory variables were continuously 
sampled breath by breath through a Hans Rudolph two 
way breathing mask (Hans Rudolph Inc, Kansas City, 
USA). The breathing mask was connected to a Vmax 
SensorMedics metabolic analyzer (Yorba Linda, Califor-
nia, USA) to assess ventilatory variables and the content 
of oxygen and carbon dioxide of expired air for calcula-
tion of oxygen uptake (VO2). VO2max was accepted when 
VO2 failed to raise despite rise in speed and ventilation 
(VE) or strong signs of exhaustion. Ventilation/perfusion 
mismatch was confirmed by impairment of ventilatory 
efficiency measured as elevated VE/VCO2 ratio at the 
anaerobic threshold calculated by the ventilatory equiva-
lent method [23]. Arterial blood gases were sampled just 
before ending the exercise test.
Simulated flight
HAST was performed while the participants were breath-
ing a hypoxic gas mixture of 15.1% oxygen balanced with 
nitrogen via a non-diffusion gas collection bag (Hans 
Rudolph Inc., Kansas City, USA) in the sitting position 
for 15 min [5]. The bag was connected to a tight fitting 
mask with a two way non-breathing valve (Hans Rudolph 
Inc., Kansas City, USA). Subsequently, the participants 
walked on the treadmill at 1.2 km·hour−1 for 5 min cor-
responding to walking along the aisle, still breathing the 
hypoxic gas.
Arterial blood gases were obtained from a radial artery 
catheter at sea level every fifth minute during the hypoxic 
exposure and at the end of the 5  min’ walk. If the per-
cutaneous oxygen saturation (SpO2 HAST) dropped ≤85% 
an extra arterial blood sample was taken. All samples 
were analysed immediately as previously described. The 
SpO2 HAST was measured continuously with a finger 
probe (NONIN 8600, Medical, Inc., Minneapolis, USA). 
A 12-lead ECG monitoring (Cardiosoft, GE Marque-
tte Medical Systems, Milwaukee, USA) was conducted 
throughout the test for evaluation of ischemia or arrhyth-
mias. Dyspnoea was scored by the BORG CR10-scale 
[24].
Statistical analysis
Demographic data are presented as mean values ± stand-
ard derivation (SD) unless otherwise specified. No 
missing values were imputed in the study. Differences 
between sea level values and HAST values were analysed 
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using Student’s paired T test. Correlation between forced 
expiratory volume after 1 s (FEV1), PaO2 SL, SpO2 SL and 
CPET variables at sea level and PaO2 HAST were assessed 
by Pearson’s correlation coefficient (r) with 95% confi-
dence intervals (CI). Statistical significance level was set 
to 5%.
Results
Thirty-two patients (male  =  21) were enrolled in the 
study to perform a HAST. Of these, 14 patients also per-
formed a CPET. Two CF patients were excluded, one 
due to an on-going infection and one due to discomfort 
related to the artery catheter. The reason for declining to 
participate in the study was primarily due to refusal to 
accept arterial cannulation.
Pre‑flight values
Table 1 shows the patient demographics, spirometric val-
ues, resting sea level blood gas values, variables during 
CPET, and blood gas values during HAST. Fifteen patients 
(50%) had a FEV1  <  50% of predicted, 16 patients (53%) 
had a SpO2 SL < 95%, and six patients (20%) had a PaO2 
SL < 9.3 kPa, cut-off values which have all been suggested 
as criteria for supplemental oxygen during air travel [3].
The average VO2max during CPET (n  =  14), was 
36.1 ± 10.5 ml·kg−1·min−1, which was 88% of predicted. 
Four patients (29%) had a VE/VCO2 ratio >35, indicating 
ventilation/perfusion mismatching.
Hypoxia altitude simulation test
In all patients, the PaO2 was considerably lower during 
HAST than at sea level (7.43 ± 0.89 vs 10.18 ± 1.19 kPa; 
p  <  0.001). Four patients (13%) fulfilled the criteria for 
supplemental oxygen during air travel based on the BTS 
recommendations (PaO2 < 6.6 kPa) [3]. Of these, all had 
FEV1 < 50% of predicted, three had SpO2 SL < 95%, and 
two had a PaO2 SL < 9.3 kPa.
The average PaO2 HAST during slow walking on the 
treadmill was 6.91 ± 0.87 kPa vs 7.55 ± 0.84 (p < 0.001) 
at rest (n  =  27), adding another eleven patients to the 
group of subjects dropping below 6.6 kPa. Seven of these 
patients (23%) had FEV1  <  50%, five (17%) had SpO2 
SL < 95%, and two patients (7%) had a PaO2 SL < 9.3 kPa.
No cardiac arrhythmias or signs of ischemia were 
observed during HAST. One patient reported mod-
erate and two reported weak dyspnoea on the BORG 
CR10 scale. However, none of these patients fulfilled 
the criteria for supplemental oxygen during air travel.
Table 1 Descriptive data of  the  participants, pulmonary function, blood gas variables and  exercise variables, reported 
as mean (SD)
BMI body mass index, FEV1 forced expiratory volume in one second, FVC forced vital capacity, SpO2 saturation for oxygen measured by pulse oximetry, VO2max maximal 
oxygen uptake, HRmax maximal heart rate during CPET
Age and anthropometry (n = 30)
 Age (yrs) 34.2 (11.81)
 Body mass (kg) 67.7 (16.35)
 Height (cm) 174.4 (9.31)
 BMI (kg/m2) 21.9 (3.65)
Pulmonary function
 FEV1 (L) 2.25 (1.12)
 FEV1 (% predicted) 58.6 (24.8)
 FVC (L) 3.60 (1.22)
 FVC (% of predicted) 79.4 (20.9)
 FEV1/FVC ratio 60.5 (12.3)
Sea level Exercise (n = 14) HAST HAST slow(n = 20) walking
Blood gas variables
 SpO2 (%) 94.8 (2.2) 88.6 (8.2) 88.6 (4.1) 87.0 (3.8)
 SaO2 (%) 95.4 (1.5) 90.1 (8.4) 89.1 (2.8) 86.3 (3.8)
 PaO2 (kPa) 10.2 (1.2) 9.8 (2.0) 7.4 (0.9) 6.9 (0.9)
 PaCO2 (kPa) 5.0 (0.4) – 5.0 (0.3) 5.0 (0.3)
 Symptoms (BORG 10 CR) 0.09 (0.23) – 0.5 (0.8) 0.9 (1.1)
CPET variables
 VE/VCO2 33.0 (4.9)
 VO2max (ml·kg−1·min−1) 36.1 (10.5)
 VO2max (% predicted) 87.5 (23.6)
 HRmax (beat·min−1) 175 (14.1)
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Correlation between pre‑flight‑ and HAST variables
Figure  1 shows the correlation between PaO2 HAST and 
pre-flight values. There was a moderate correlation 
between PaO2 HAST and FEV1, PaO2 SL and SaO2 SL, while 
no significant correlation between PaO2 HAST and SpO2 
SL was observed. Data from the CPET (Fig. 2) showed a 
strong correlation between PaO2 HAST and PaO2 CPET, 
SpO2 CPET, VE/VCO2 CPET and SaO2 CPET. In addition, a 
moderate correlation was observed between PaO2 HAST 
and VO2max.
Discussion
So far, no studies have demonstrated a simple and reliable 
method for identifying which CF-patients will become 
severely hypoxemic during air travel. In the present study, 
30 CF patients were examined during a standardized 
hypoxia altitude simulation test. Four out of 30 patients 
dropped to a PaO2 < 6.6 kPa during HAST, thereby fulfill-
ing an internationally accepted criterion for supplemen-
tal oxygen during air travel [3, 4]. In addition, 11 patients 
dropped below PaO2  <  6.6  kPa during slow walking on 
the treadmill while breathing the hypoxic gas mixture, 
underlining the impact of even very light physical activity 
during hypoxic conditions. PaO2 HAST was modestly cor-
related to sea level FEV1, PaO2 and, SaO2 at rest. How-
ever, a strong correlation was observed between PaO2 
HAST and variables obtained during maximal exercise, i.e. 
PaO2 CPET, SpO2 CPET and VO2max, and a strong negative 
correlation was observed between PaO2 HAST and the VE/
VCO2 ratio.
A methodological limitation of the study was that only 
14 of the 30 patients performed a CPET. However, a post 
hoc power calculation for a correlation coefficient of 0.7 
revealed that 13 participants were sufficient for detecting 
a significant difference from zero with 80% power.
Pre‑flight variables at rest
The usefulness of FEV1 in the pre-flight assessment has 
been debated. In a study of 69 adult CF patients, Peck-
ham et  al. found that FEV1 was significantly correlated 
Fig. 1 Relationships between arterial oxygen partial pressure (PaO2) during Hypoxia Altitude Simulation Test (HAST) and forced expiratory volume 
in one second (FEV1) (a), pulse oximetry (SpO2) (b), PaO2 (c) and SaO2 at rest (d)
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to PaO2 HAST [18]. In a study of 87 children with CF who 
travelled by air, Buchdahl et al. concluded that FEV1 was 
a better predictor of in-flight desaturation than HAST 
[25]. The results of the present study confirm a mod-
est correlation between PaO2 HAST and FEV1. The four 
CF-patients who fulfilled the criteria for supplemental 
oxygen all had a FEV1 below 50% of predicted, which is 
in agreement with other studies investigating adult CF-
patients [17, 18]. It is, however, worth noting that 11 
patients with a FEV1 < 50% predicted in the present study 
had a negative HAST (PaO2 ≥  6.6 kPa). With regard to 
COPD patients, FEV1 has proven to be a poor predictor 
of in-flight hypoxaemia [10, 11]. The revised BTS recom-
mendations regarding air travel state a poor relationship 
between FEV1 and hypoxaemia in passengers with pul-
monary disease in general [3]. According to the literature, 
FEV1 seems to be a somewhat better predictor of in-flight 
hypoxaemia in CF patients than in patients with COPD, 
but both the present and previous studies are too small 
to draw reliable conclusions of whether CF patients with 
a FEV1  >  50% predicted can travel safely by air without 
supplementary oxygen.
Symptoms during HAST were in general mild in most 
patients, but increased slightly during slow walking. Only 
one of the patients that fulfilled the criteria for supple-
mental oxygen reported symptoms (weak), indicating 
that HAST was well tolerated in those who became very 
hypoxic.
Pulse oximetry is easy to perform and available at most 
medical centres. However, the latest BTS recommenda-
tions (2011) state that sea level SpO2 does not predict 
hypoxaemia as accurately as previously assumed [3]. This 
is in line with the current study showing that there was no 
significant correlation between pre-flight SpO2 and PaO2 
HAST. One of the patients with a resting pulse oximetry ≥ 
95% fulfilled the criteria for supplementary oxygen in the 
present study. Similar observations have been presented in 
a study on COPD patients [11]. Thus, a SpO2 ≥ 95% does 
not seem to be a reliable cut off value for travelling safely 
without supplemental oxygen. In a recently published 
Fig. 2 Relationships between arterial oxygen partial pressure (PaO2) during Hypoxia Altitude Simulation Test (HAST) and physiological variables 
during exercise; maximal oxygen uptake (a), ventilatory eqvivalent for carbon dioxide ratio (VE/VCO2) (b), pulse oximetry (SpO2) (c) and PaO2 (d)
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study, an algorithm employing a combination of pulse 
oximetry at rest and during a 6 min walking test was used 
for pre-flight screening of COPD patients. It was found 
that this combination was a reliable tool for discriminat-
ing between COPD patients who can travel without sup-
plementary oxygen, those who need such treatment, and 
the group of patients who needs more advanced pre-flight 
testing with HAST [26]. This algorithm has not been eval-
uated in relation to patients with CF.
In medical guidelines for air travel, it has been claimed 
that a stable pre-flight PaO2 exceeding 9.3  kPa is suf-
ficient for travelling by air without supplemental oxy-
gen [2, 5]. This has been contradicted by several studies 
on COPD patients [10, 11]. In the current study, two 
patients who required supplemental oxygen according 
to the HAST had a pre-flight PaO2 above 9.3  kPa (9.5 
and 10.3 kPa). Hence, using pre-flight PaO2 > 9.3 kPa as 
a criterion for acceptable PaO2 levels during air travel in 
patients with CF does not exclude in-flight hypoxaemia.
Pre‑flight variables during exercise
The current study shows that PaO2 and SpO2 during 
maximal exercise are strongly correlated with PaO2 HAST. 
Also, the pre-flight VO2max showed a stronger correlation 
to PaO2 HAST than FEV1, SpO2 and PaO2 measured at rest. 
These findings are in agreement with previous findings in 
COPD patients during both hypobaric chamber expo-
sure at 2438  m and during a commercial flight [10, 11, 
27], showing that pre-flight aerobic capacity and exercise 
desaturation were strongly correlated with the in-flight 
PaO2. Since exercise testing is a part of the annual assess-
ment at most CF-centres, exercise desaturation may be a 
good indicator for need of supplemental oxygen during 
air travel, also for CF patients with severe lung disease. In 
general, CPET is shown to be well tolerated in severely ill 
patients [28–30].
The ventilatory efficiency defined by ventilation rela-
tive to CO2-production (VE/VCO2) ratio [23] has not 
previously been studied as a variable in relation to devel-
opment of in-flight hypoxaemia in patients with lung dis-
ease. In CF patients, hypoxaemia is mainly related to a 
mismatch between ventilation and perfusion in the lung 
caused by the chronic inflammation and mucus plug-
ging [31], and an elevated VE/VCO2 ratio measured at 
the anaerobic threshold indicates an uneven distribution 
of ventilation and perfusion [23]. The VE/VCO2 ratio is 
highly reproducible, and the degree of elevation has been 
shown to reflect the severity of ventilation-perfusion mis-
matching [29]. The pre-flight VE/VCO2 ratio in the pre-
sent study showed a strong negative correlation to PaO2 
HAST. The two patients with the highest VE/VCO2 ratio 
both fulfilled the criteria for supplemental oxygen, and 
those patients who had a moderate elevation of VE/VCO2 
ratio had a moderate reduction in PaO2 HAST. It should be 
noted that the VE/VCO2 ratio can also be elevated dur-
ing hyperventilation due to anxiety or discomfort wear-
ing a tight mask. However, no objective (high respiratory 
exchange ratio) or subjective sign of hyperventilation was 
observed during the test.
Taken together, these results indicate that exercise test-
ing might be of value in the pre-flight assessment of lung 
patients, including patients with CF.
Hypoxia altitude simulation test
HAST has proven to be a practical and reliable method 
for advanced pre-flight evaluation of patients with lung 
disease [32], and is today considered to be the ‘gold 
standard’ in clinical practise [26, 33]. In the present study, 
HAST has been used as the reference method for detect-
ing development of hypoxaemia under hypoxic condi-
tions. It should be noted, however, that Buchdahl et  al. 
observed a poor relationship between SpO2 obtained 
during HAST and during a real flight [25]. This could be 
due to the fact that SpO2 seems to be inferior to PaO2 
as a tool for predicting development of in-flight hypox-
aemia [34]. As shown in other groups of lung patients, 
even light exercise seems to aggravate hypoxaemia under 
hypoxic conditions [10, 26]. This might be of importance 
for patients during long haul flights where the passengers 
are encouraged to exercise and also are in need of visit-
ing the lavatory. Thus, in the authors’ opinion, light exer-
cise should preferably be included in the HAST protocol. 
Other hazards than hypoxaemia during air travel may in 
general be the risk of venous thromboembolism due to 
immobilisation [35]. This condition may easily be pre-
vented by use of compression stocking in combination 
with doing calf-muscle exercise. In-flight transmission of 
infectious disease is also a risk for CF patients [36].
Conclusions
In summary, we have studied the relationship between 
the development of hypoxaemia during a simulated flight 
and regularly used tests of pulmonary function, blood 
gases and gas exchange variables during exercise in a 
group of adult patients with CF. Furthermore, the effect 
of slow walking during HAST was studied showing a pro-
nounced aggravation of the hypoxaemia.
Variables obtained during CPET showed a stronger 
correlation to in-flight hypoxaemia than spirometric 
values and blood gas values obtained at rest. This is in 
accordance with studies on COPD patients. Thus, future 
studies should probably concentrate on establishing reli-
able cut off values during CPET, making them suitable for 
use in pre-flight screening of patients with CF.
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